Alira Health says global biologics CDMO market reaches $23.2 billion in 2025

  • Alira Health released its 2026 Biologics Contract Manufacturing Report, pegging the global biologics CDMO market at $23.2 billion in 2025.
  • Competitive advantage is shifting from scale to specialized manufacturing, regulatory execution, commercial track record as biologics complexity rises.
  • Top 10 CDMOs control 55% of market value, signaling sponsor preference for large, experienced global providers.
  • Scarce commercial-scale GLP-1 peptide, AAV gene therapy capacity supports pricing power, with sponsors paying up for supply security.
  • M&A rose to 29 transactions in 2025; capability drove nearly 80% of deals; 84% of USD 13.3 billion investment went to US sites.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alira Health Ventures LLC published the original content used to generate this news brief on July 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.